Literature DB >> 10948115

DNA-Based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection.

P Sepulveda1, M Hontebeyrie, P Liegeard, A Mascilli, K A Norris.   

Abstract

A complement regulatory protein (CRP) of Trypanosoma cruzi was evaluated as a vaccine candidate in a murine model of experimental T. cruzi infection. Recombinant CRP derived from an Escherichia coli expression system and a plasmid encoding the full-length crp structural gene under the control of a eukaryotic promoter were used to immunize BALB/c mice. Immunization with both protein and DNA vaccines resulted in a Th1-type T-cell response, comparable antibody titers, and similar immunoglobulin G isotype profiles. Only mice immunized with the crp DNA plasmid produced antibodies capable of lysing the parasites in the presence of complement and were protected against a lethal challenge with T. cruzi trypomastigotes. These results demonstrate the superiority of DNA immunization over protein immunization with the recombinant CRP. The work also supports the further investigation of CRP as a component of a multigene, anti-T. cruzi DNA vaccine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10948115      PMCID: PMC101717          DOI: 10.1128/IAI.68.9.4986-4991.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi.

Authors:  Z BRENER
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1962 Nov-Dec       Impact factor: 1.846

2.  Control of Chagas disease. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1991

3.  Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.

Authors:  B Wizel; N Garg; R L Tarleton
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

4.  "Autoimmune rejection" of neonatal heart transplants in experimental Chagas disease is a parasite-specific response to infected host tissue.

Authors:  R L Tarleton; L Zhang; M O Downs
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor.

Authors:  K A Norris; B Bradt; N R Cooper; M So
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

7.  Identification of the gene family encoding the 160-kilodalton Trypanosoma cruzi complement regulatory protein.

Authors:  K A Norris; J E Schrimpf; M J Szabo
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

8.  The relative contribution of antibody production and CD8+ T cell function to immune control of Trypanosoma cruzi.

Authors:  S Kumar; R L Tarleton
Journal:  Parasite Immunol       Date:  1998-05       Impact factor: 2.280

9.  Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies.

Authors:  A U Krettli; Z Brener
Journal:  J Immunol       Date:  1982-05       Impact factor: 5.422

10.  Humoral immune response to the Trypanosoma cruzi complement regulatory protein as an indicator of parasitologic clearance in human Chagas' disease.

Authors:  K A Norris; L M Galvão; J E Schrimpf; J R Cançado; A U Krettli
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

View more
  27 in total

1.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Trypanosoma cruzi infection induces a massive extrafollicular and follicular splenic B-cell response which is a high source of non-parasite-specific antibodies.

Authors:  Daniela A Bermejo; María C Amezcua Vesely; Mahmood Khan; Eva V Acosta Rodríguez; Carolina L Montes; Maria C Merino; Kai Michael Toellner; Elodie Mohr; Dale Taylor; Adam F Cunningham; Adriana Gruppi
Journal:  Immunology       Date:  2010-09-28       Impact factor: 7.397

3.  Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.

Authors:  Ingrid Aguilar-Be; Renata da Silva Zardo; Edilma Paraguai de Souza; Gulnara Patrícia Borja-Cabrera; Miguel Rosado-Vallado; Mirza Mut-Martin; Maria del Rosario García-Miss; Clarisa Beatriz Palatnik de Sousa; Eric Dumonteil
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

4.  Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice.

Authors:  Eric Dumonteil; Javier Escobedo-Ortegon; Norma Reyes-Rodriguez; Arletty Arjona-Torres; Maria Jesus Ramirez-Sierra
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 5.  The influence of selenium on immune responses.

Authors:  Peter R Hoffmann; Marla J Berry
Journal:  Mol Nutr Food Res       Date:  2008-11       Impact factor: 5.914

6.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

7.  Specific humoral immunity versus polyclonal B cell activation in Trypanosoma cruzi infection of susceptible and resistant mice.

Authors:  Marianne A Bryan; Siobhan E Guyach; Karen A Norris
Journal:  PLoS Negl Trop Dis       Date:  2010-07-06

8.  Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.

Authors:  Shivali Gupta; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2010-08-10

9.  Sequence diversity of the Trypanosoma cruzi complement regulatory protein family.

Authors:  M Beucher; K A Norris
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

10.  Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.

Authors:  Eduardo L V Silveira; Carla Claser; Filipe A B Haolla; Luiz G Zanella; Mauricio M Rodrigues
Journal:  Clin Vaccine Immunol       Date:  2008-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.